Company Profile

Lydex Pharmaceuticals LLC
Profile last edited on: 10/8/20      CAGE: 7ULU5      UEI: M8UCBK1HFJN3

Business Identifier: HDACi for liver ischemia-reperfusion injury
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

330 Concord Street Unit 6A
Charleston, SC 29401
Location: Single
Congr. District: 01
County: Charleston

Public Profile

Lydex Pharmaceuticals is working towards development of next-generation inhibitors for multiple diseases. The team is initially tackling investigation and developments of compounds targeting the key enzymes responsible for organ damage, inflammation and rejection after transplant. The effort is to develop a novel approach to preventing reperfusion-related organ damage after liver transplant. Lydex Pharmaceuticals is developing compounds - known as histone deacetylase (HDAC) inhibitors - to help prevent ischemia-reperfusion injury. Normally investigated for their potency as anti-cancer drugs, these inhibitors affect the level of gene expression within a cell. Lydex and MUSC researchers have shown that targeting specific HDAC enzymes within the liver markedly reduces both inflammation and tissue damage after reperfusion.Normally, HDAC inhibitors are potent but have potential toxic effects as they hit unintended enzymes within the cell. The lead compound in development by Lydex promises high potency while also doing a better job of targeting only the enzymes involved in ischemia-reperfusion injury, which greatly minimizes the risk of toxic effects.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Sherine Chan -- Co-Founder

  C James Chou -- Founder

  Richard Himes -- Founder

  Zhi Zhong

Company News

There are no news available.